Manish Manrai

Dr. Manish Manrai

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
MMManish Manrai
Manish Manrai
SDSaurabh Dawra
Saurabh Dawra
RKRajan Kapoor
Rajan Kapoor
SSSharad Srivastava
Sharad Srivastava
ASAnupam Singh
Anupam Singh
Anemia in a patient with cirrhosis is a clinically pertinent but often overlooked clinical entity. Relevant guidelines highlight the algorithmic approach of managing a patient of cirrhosis presenting with acute variceal hemorrhage but day-to-day management in hospital and out-patient raises multiple dilemmas: Whether anemia is a disease complication or a part of the disease spectrum? Should iron, folic acid, and vitamin B complex supplementation and nutritional advice, suffice in those who can perform tasks of daily living but have persistently low hemoglobin. How does one investigate and manage anemia due to multifactorial etiologies in the same patient: Acute or chronic blood loss because of portal hypertension and bone marrow aplasia secondary to hepatitis B or C viremia? To add to the clinician’s woes the prevalence of anemia increases with increasing disease severity. We thus aim to critically analyze the various pathophysiological mechanisms complicating anemia in a patient with cirrhosis with an emphasis on the diagnostic flowchart in such patients and proposed management protocols thereafter.

21 October 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MMManish Manrai
Manish Manrai
TTT V S V G K Tilak
T V S V G K Tilak
SDSaurabh Dawra
Saurabh Dawra
SSSharad Srivastava
Sharad Srivastava
ASAnupam Singh
Anupam Singh
Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities

14 March 2024 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
MMManish Manrai
Manish Manrai
AJAtul A Jha
Atul A Jha
SDSaurabh Dawra
Saurabh Dawra
APAditya Vikram Pachisia
Aditya Vikram Pachisia
Inflammatory bowel disease (IBD) is a group of heterogeneous chronic inflammatory diseases of the gut presenting with intestinal and extraintestinal manifestations. Most cases fit in predominantly two types, namely, ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily in the past three decades. Focused research has resulted in many therapeutic options. Biologics (derived from humans or animals) and small molecules have emerged as the cornerstone in the management of IBD and have become widely available. Currently, monoclonal antibodies against tumor necrosis factor-alpha (infliximab, adalimumab, certolizumab, and golimumab), integrins (vedolizumab and natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab), along with small molecules (tofacitinib), are approved for use. This article summarizes various aspects of these drugs, like clinical pharmacology, indications for use in IBD, safety in pregnancy and lactation, and the adverse effects profile based on the studies leading to their approval. This review also focuses on the recent advances and future perspectives specific to biologics in IBD.

26 April 2023 in World Journal of Clinical Cases
Verified
Journal Article
Open access
MMManish Manrai
Manish Manrai
SDSaurabh Dawra
Saurabh Dawra
ASAnupam K Singh
Anupam K Singh
DJDaya Krishna Jha
Daya Krishna Jha
RKRakesh Kochhar
Rakesh Kochhar
This review summarized the current controversies in the management of acute pancreatitis (AP). The controversies in management range from issues involving fluid resuscitation, nutrition, the role of antibiotics and antifungals, which analgesic to use, role of anticoagulation and intervention for complications in AP. The interventions vary from percutaneous drainage, endoscopy or surgery. Active research and emerging data are helping to formulate better guidelines. The available evidence favors crystalloids, although the choice and type of fluid resuscitation is an area of dynamic research. The nutrition aspect does not have controversy as of now as early enteral feeding is preferred most often than not. The empirical use of antibiotics and antifungals are gray zones, and more data is needed for conclusive guidelines. The choice of analgesic is being studied, and the recommendations are still evolving. The position of using anticoagulation is still awaiting consensus. The role of intervention is well established, although the modality is constantly changing and favoring endoscopy or percutaneous drai nage rather than surgery. It is evident that more multicenter randomized control led trials are required for establishing the standard of care in these crucial management issues of AP to improve the morbidity and mortality worldwide.

1 October 2019 in Medical Journal Armed Forces India
Verified
Journal Article
Closed access
STSandeep Thareja
Sandeep Thareja
MMManish Manrai
Manish Manrai
RSRajat Shukla
Rajat Shukla
ASAtul Kumar Sood
Atul Kumar Sood
AJAtul A Jha
Atul A Jha
SMSachin Maggo
Sachin Maggo

1 April 2022 in Medical Journal Armed Forces India
Verified
Journal Article
Closed access
PSP.K. Sharma
P.K. Sharma
SSS. Salaria
S. Salaria
MMManish Manrai
Manish Manrai
SSS. Srivastava
S. Srivastava
DKD. Kumar
D. Kumar
ASA.R. Singh
A.R. Singh